Bristol’s Fibrotic Game Plan: Promedior Acquisition Hinges On Phase II Results
This article was originally published in The Pink Sheet Daily
Bristol’s third deal in anti-fibrosis field in past year could give it intravenous, disease-modifying candidate for myelofibrosis and idiopathic fibrosis.
You may also be interested in...
Biopharma financing totaled $9.7 billion, almost half from follow-on public offerings; there was big consolidation in the generics and health services industries. AstraZeneca signed a dozen partnerships, many of which focused on oncology.
Novartis and Amgen exchange rights around CNS candidates in Alzheimer’s and migraine. AstraZeneca out-licenses global rights, except for Japan and Asia, for Phase III psoriasis candidate brodalumab to Valeant.
$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications
Recent deal-making has brought larger, deeper-pocketed players into the IPF space, but Promedior still likes its approach of going it alone with Pentraxin-2-based therapies in fibrotic disease.